Literature DB >> 10546885

The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy.

T Saint-Marc, J L Touraine.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10546885     DOI: 10.1097/00002030-199910220-00035

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  8 in total

Review 1.  Adipose Tissue in HIV Infection.

Authors:  John R Koethe
Journal:  Compr Physiol       Date:  2017-09-12       Impact factor: 9.090

Review 2.  Mitochondrial toxicity and HIV therapy.

Authors:  A J White
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

3.  Mitochondrial Toxicity Associated with Nucleoside Reverse Transcriptase Inhibitor Therapy.

Authors:  Cecilia M. Shikuma; Bruce Shiramizu
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

Review 4.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 5.  Lipodystrophy syndrome in patients with HIV infection: quality of life issues.

Authors:  E Martínez; M A Garcia-Viejo; L Blanch; J M Gatell
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  Evaluation and management of dyslipidemia in patients with HIV infection.

Authors:  Michael L Green
Journal:  J Gen Intern Med       Date:  2002-10       Impact factor: 5.128

Review 7.  Saquinavir soft gelatin capsule: a comparative safety review.

Authors:  J Gill; J Feinberg
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

8.  Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.

Authors:  M Isabel Gonzalez-Tome; Jose Tomas Ramos Amador; M Jose Mellado Peña; M Luisa Navarro Gomez; Pablo Rojo Conejo; Pablo Martin Fontelos
Journal:  BMC Infect Dis       Date:  2008-10-22       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.